Address correspondence to Dr Nicholas E. Johnson, Virginia Commonwealth University, 1101 East Marshall St, Box 980599, Richmond, VA 23298, [email protected].
RELATIONSHIP DISCLOSURE: Dr Johnson has received personal compensation in the range of $500 to $4999 for serving as a consultant for Acceleron Pharma, Avidity Biosciences, Dyne Therapeutics, Entrada Therapeutics, Juvena Therapeutics, Sarepta Therapeutics, Triplet Therapeutics, and Vertex Pharmaceuticals and for serving on a scientific advisory or data safety monitoring board for Biogen; in the range of $10,000 to $49,999 for serving as a consultant for Arthex Biotech; and in the range of $50,000 to $99,999 for serving as a consultant for ML Bio Solutions. Dr Johnson holds stock in ML Bio Solutions and has received intellectual property interests from a discovery or technology relating to health care. The institution of Dr Johnson has received research support from AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, Fulcrum Therapeutics, ML Bio Solutions, Novartis Gene Therapies, Sarepta Therapeutics, Triplet Therapeutics, and Vertex Pharmaceuticals. Dr Statland has received personal compensation in the range of $500 to $4999 for serving as a consultant for Arrowhead Pharmaceuticals, Mitsubishi Tanabe Pharma, and ML Bio Solutions, and for serving on a scientific advisory or data safety monitoring board for Avidity Biosciences; in the range of $5000 to $9999 for serving on a scientific advisory or data safety monitoring board for Fulcrum Therapeutics; and in the range of $10,000 to $49,999 for serving on a scientific advisory or data safety monitoring board for Dyne Therapeutics. The institution of Dr Statland has received research support from Friends of FSH Research, FSHD Canada, FSHD Society, the Muscular Dystrophy Association, and the National Institutes of Health.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Johnson and Statland report no disclosures.